Tracking temporal shifts of peripheral blood NLR, PLR, and ALB: a prognostic tool for PD-1 inhibitor efficacy in advanced malignant melanoma
Open Access
- 5 January 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1704359
Abstract
Objective: PD-1 monoclonal antibodies are cornerstone therapies for advanced malignant melanoma, yet treatment response varies greatly between patients. This study investigated temporal changes in peripheral blood inflammatory and nutritional parameters during PD-1 therapy, examined their associations with clinical outcomes, and identified prognostic biomarkers. Methods: A retrospective analysis was conducted on 99 patients with advanced malignant melanoma who received PD-1 monoclonal antibody treatment at the First Affiliated Hospital of Zhengzhou University (January 2019–September 2024). Imaging evaluations (CT/MRI, with PET-CT for suspected distant metastasis) were performed at baseline (T0, before treatment), the end of the 2nd cycle (T2), and the end of the 4th cycle (T4) to assess treatment response per the immune-related Response Evaluation Criteria in Solid Tumors (irRECIST).After four treatment cycles, patients were stratified into a clinical benefit group (complete response [CR] + partial response [PR] + stable disease [SD], n=68) and a non-benefit group (progressive disease [PD], n=31) based on the immune-related Response Evaluation Criteria in Solid Tumors (irRECIST). Peripheral blood samples were collected at five time points: baseline (T0), post-first cycle (T1), post-second cycle (T2), post-third cycle (T3), and post-fourth cycle (T4). Dynamic changes in neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), serum albumin (ALB), and prognostic nutritional index (PNI) were compared between groups. Line graphs and box plots were used to visualize indicator trends, while logistic regression and receiver operating characteristic (ROC) curves were applied to evaluate prognostic value. Results: Non-benefit patients showed NLR peaks at T2 and PLR peaks at T1, while benefit patients had stable levels. ALB and PNI were higher and stable in the benefit group (P<0.05). A model combining T1PLR, T1ALB, and T2NLR achieved an AUC of 0.89 (sensitivity 0.90, specificity 0.79). Conclusion: Dynamic monitoring of peripheral blood NLR, PLR, and ALB provides critical insights for predicting PD-1 immunotherapy efficacy in patients with advanced malignant melanoma. These indicators hold promise as potential clinical biomarkers to guide the development of individualized treatment strategies.Keywords
Funding Information
- National Key Research and Development Program of China
This publication has 53 references indexed in Scilit:
- Dynamic blood-based biomarkers predict early response to ipilimumab and nivolumab in advanced melanomaClinical and Translational Oncology, 2025
- Prognostic utility of the CALLY index in metastatic melanoma: building a nomogram for Patients on Anti-PD-1 therapyClinical and Translational Oncology, 2025
- Advancements in Melanoma Therapies: From Surgery to ImmunotherapyCurrent Treatment Options in Oncology, 2024
- Nutritional status as prognostic factor of advanced oesophageal cancer patients treated with immune checkpoint inhibitorsClinical Nutrition, 2023
- Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040JAMA Dermatology, 2022
- Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint InhibitorsJAMA Network Open, 2021
- High neutrophil‐to‐lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD‐1 inhibitor monotherapyCancer, 2019
- The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced‐stage cancer treated with immunotherapyCancer, 2018
- Nivolumab: A Review in Advanced MelanomaDrugs, 2015
- The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to DateDrugs, 2015